Illumina, Inc.’s Non-Invasive Verifi® Prenatal Test Using Cfdna Significantly Reduces False Positive Rate Of Fetal Aneuploidy Detection Compared To Current Standard Pregnancy Screening Practices

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced that in a direct comparison of non-invasive prenatal testing (NIPT) using cell free DNA (cfDNA) to standard prenatal aneuploidy screening in a general obstetrical population, the verifi® prenatal test1 significantly reduced the rate of false positive results for the detection of fetal trisomies 21 and 18. In addition, the study demonstrated that the verifi® prenatal test performs consistently well in all pregnant women, regardless of their risk level for fetal aneuploidy.

Help employers find you! Check out all the jobs and post your resume.